These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 25932758)

  • 41. Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? Study protocol for a randomized controlled trial [NCT00120978].
    Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Rousseau R;
    BMC Pulm Med; 2006 Feb; 6():3. PubMed ID: 16460562
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease.
    Mahler DA; Wire P; Horstman D; Chang CN; Yates J; Fischer T; Shah T
    Am J Respir Crit Care Med; 2002 Oct; 166(8):1084-91. PubMed ID: 12379552
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Onbrez breezhaler to control chronic obstructive pulmonary disease].
    Perspect Infirm; 2012; 9(5):66. PubMed ID: 22978140
    [No Abstract]   [Full Text] [Related]  

  • 44. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pulmonary medicine. Two new drugs for the treatment of COPD].
    Rochat T
    Rev Med Suisse; 2011 Jan; 7(278):145-6, 148-9. PubMed ID: 21400948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of the Chinese herb formula Yufeining on stable chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial.
    Hong M; Hong C; Chen H; Ke G; Huang J; Huang X; Liu Y; Li F; Li C
    Medicine (Baltimore); 2018 Sep; 97(39):e12461. PubMed ID: 30278529
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Efficacy of the correct utilization of inhalation devices in patients with chronic obstructive pulmonary disease: randomized clinical trial].
    Epelde F
    Med Clin (Barc); 2011 Sep; 137(8):377. PubMed ID: 21450318
    [No Abstract]   [Full Text] [Related]  

  • 48. Phosphodiesterase 4 inhibitors: antiinflammatory therapy for chronic obstructive pulmonary disease at last?
    Kerstjens HA; Timens W
    Am J Respir Crit Care Med; 2003 Oct; 168(8):914-5. PubMed ID: 14555456
    [No Abstract]   [Full Text] [Related]  

  • 49. Targets of Neutrophil Influx and Weaponry: Therapeutic Opportunities for Chronic Obstructive Airway Disease.
    Mårdh CK; Root J; Uddin M; Stenvall K; Malmgren A; Karabelas K; Thomas M
    J Immunol Res; 2017; 2017():5273201. PubMed ID: 28596972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhaled steroids in chronic obstructive pulmonary disease.
    Anthonisen NR
    Can Respir J; 2002; 9(1):11-2, 16-7. PubMed ID: 11856985
    [No Abstract]   [Full Text] [Related]  

  • 51. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy.
    Onoue S; Misaka S; Kawabata Y; Yamada S
    Expert Opin Drug Deliv; 2009 Aug; 6(8):793-811. PubMed ID: 19558334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adherence to long-acting inhaled therapies among patients with chronic obstructive pulmonary disease (COPD).
    Cecere LM; Slatore CG; Uman JE; Evans LE; Udris EM; Bryson CL; Au DH
    COPD; 2012 Jun; 9(3):251-8. PubMed ID: 22497533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Five questions in chronic obstructive pulmonary disease.
    Miravitlles M
    Expert Rev Respir Med; 2013 Apr; 7(2 Suppl):1-2. PubMed ID: 23551018
    [No Abstract]   [Full Text] [Related]  

  • 54. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
    Martínez FJ
    Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
    [No Abstract]   [Full Text] [Related]  

  • 55. Drugs for chronic obstructive pulmonary disease.
    Treat Guidel Med Lett; 2007 Nov; 5(63):95-100. PubMed ID: 17938609
    [No Abstract]   [Full Text] [Related]  

  • 56. Phenotype/endotype-driven therapy in COPD: potential economic implications.
    Antoniu SA
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):421-3. PubMed ID: 23977968
    [No Abstract]   [Full Text] [Related]  

  • 57. World Asthma and COPD Forum. Tackling asthma, COPD and allergic diseases.
    D'Amato G
    IDrugs; 2008 Jul; 11(7):486-8. PubMed ID: 18600593
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical profile of roflumilast].
    Izquierdo Alonso JL
    Arch Bronconeumol; 2010 Dec; 46 Suppl 10():25-32. PubMed ID: 21316553
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In reference to "Nebulized bronchodilators instead of metered-dose inhalers for obstructive pulmonary symptoms".
    LaBrin J
    J Hosp Med; 2016 Apr; 11(4):311. PubMed ID: 26748681
    [No Abstract]   [Full Text] [Related]  

  • 60. [Chronic obstructive pulmonary disease. No increased survival with combination therapy].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2007 Nov; 30(11):428-9. PubMed ID: 18062342
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.